Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

AZ, Pfizer add new drugs

Posted 6 December 2021 AM

Over the past week, the TGA approved three new medicines, including Pfizer's Ngenla which will be considered for government-subsidy for paediatric growth hormone deficiency at the PBAC's first meeting in the new year.

Ngenla, a once-weekly, long-acting, recombinant human growth hormone, marks one of the first in a long list of medicines submitted to the committee's March meeting under parallel processing that have been TGA approved.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.